Eli Lilly at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

Eli Lilly takes part in 3 sessions at ESMO 2026 in Madrid, and exhibits at Booth 1058. Its program centres on non-small cell lung cancer with the KRAS G12C mutation and on hormone receptor-positive, HER2-negative breast cancer. It also covers practical ways to improve communication, treatment adherence and care delivery for patients.

Organization

ESMO 2026 Attendance

Large pharmaExhibitor

Global pharmaceutical company whose oncology medicines include abemaciclib, selpercatinib and pirtobrutinib.

Booth

Exhibiting at Booth 1058

Satellite

Sat Oct 24
13:00–14:30

Eli Lilly and Company - KRAS G12C-Mutant NSCLC Across the Disease Continuum: From Biology and Unmet Needs to Optimizing Care

Sponsored session · with Chelsea and Westminster Hospital

Lung & thoracic cancers

Satellite

Sat Oct 24
18:30–20:00

Eli Lilly and Company - Navigating the Therapeutic Crossroads in HR+ HER2- Breast Cancer: Defining Your Next Clinical Direction

Sponsored session

Breast cancer

Satellite

Sun Oct 25
13:15–14:45

Lilly - Translating treatment decisions into patient Palacio Municipal outcomes: practical approaches to communication, adherence and care delivery

Sponsored session

Nursing & supportive care

Instantly find 20 buyers from Eli Lilly

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction